The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

To provide a fluorinated ether compound, a fluorinated ether composition and a coating liquid excellent in chemical resistance, an article having a surface layer excellent in chemical resistance and a method for producing it, and a method for producing a fluorinated ether compound excellent in chemical resistance.

A fluorinated ether compound which has a first partial structure represented by the following formula (1) and a second partial structure represented by the following formula (2), and which has at least five first partial structures, or has at least two second partial structures:

—OR.sup.f12—  (1)

—OR.sup.f13—  (2)

wherein R.sup.f12 is a C.sub.1-6 fluoroalkylene group, and R.sup.f13 is a group having a fluorinated cyclic structure which may have a hetero atom.

To provide a fluorinated ether compound, a fluorinated ether composition and a coating liquid excellent in chemical resistance, an article having a surface layer excellent in chemical resistance and a method for producing it, and a method for producing a fluorinated ether compound excellent in chemical resistance.

A fluorinated ether compound which has a first partial structure represented by the following formula (1) and a second partial structure represented by the following formula (2), and which has at least five first partial structures, or has at least two second partial structures:

—OR.sup.f12—  (1)

—OR.sup.f13—  (2)

wherein R.sup.f12 is a C.sub.1-6 fluoroalkylene group, and R.sup.f13 is a group having a fluorinated cyclic structure which may have a hetero atom.

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

A composition comprised of a component selected from the group consisting of a biobased bis-alkyl succinate and a biobased bis-alkyl sebacate, each derived, for example, from the esterification of biobased diacid such as succinic acid or sebacic acid, and a biobased alcohol and a biobased polyester.

A composition comprised of a component selected from the group consisting of a biobased bis-alkyl succinate and a biobased bis-alkyl sebacate, each derived, for example, from the esterification of biobased diacid such as succinic acid or sebacic acid, and a biobased alcohol and a biobased polyester.

Disclosed are a carboxylate represented by formula (I), a carboxylic acid generator, a resin, and a resist composition including the same.

##STR00001##

wherein R.sup.1 and R.sup.2 each represent a hydroxy group, —O—R.sup.10, etc.; R.sup.4, R.sup.5, R.sup.7 and R.sup.8 each represent a halogen atom, a haloalkyl group, etc.; R.sup.10 represents an acid-labile group; A.sup.1 and A.sup.2 each represent a hydrocarbon group; m1 represents an integer of 1 to 5, m2 and m8 represent an integer of 0 to 5, m4, m5 and m7 represent an integer of 0 to 4, 1≤m1+m7≤5, 0≤m2+m8≤5; X.sup.0 represents a single bond, a hydrocarbon group which may have a substituent; R.sup.bb1 represents a hydrogen atom, a halogen atom, etc.; X.sup.10 represents a single bond, *—O—**, etc.; and L.sup.10 represents a single bond or a hydrocarbon group which may have a substituent.

Disclosed are a carboxylate represented by formula (I), a carboxylic acid generator, a resin, and a resist composition including the same.

##STR00001##

wherein R.sup.1 and R.sup.2 each represent a hydroxy group, —O—R.sup.10, etc.; R.sup.4, R.sup.5, R.sup.7 and R.sup.8 each represent a halogen atom, a haloalkyl group, etc.; R.sup.10 represents an acid-labile group; A.sup.1 and A.sup.2 each represent a hydrocarbon group; m1 represents an integer of 1 to 5, m2 and m8 represent an integer of 0 to 5, m4, m5 and m7 represent an integer of 0 to 4, 1≤m1+m7≤5, 0≤m2+m8≤5; X.sup.0 represents a single bond, a hydrocarbon group which may have a substituent; R.sup.bb1 represents a hydrogen atom, a halogen atom, etc.; X.sup.10 represents a single bond, *—O—**, etc.; and L.sup.10 represents a single bond or a hydrocarbon group which may have a substituent.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.